Go to illumina.com

GRAIL Acquisition

Investors

Download item year list

Date Download Description

June 26, 2024

GRAIL Spin-off - Form 8937 (opens in new window)

4.41 MB

September 30, 2021

Form 8937 (opens in new window)

1.45 MB

Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Illumina, Inc., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Illumina, Inc. to send you the requested Investor Email Alert updates.

* Required

Mailing Lists *

Press Releases
Events
Presentations
SEC Filings
End of Day Stock Quote

Email Address *

Email Alert Sign Up Confirmation

Contact Us

General Inquiries

Salli Schwartz, Vice President
lllumina Investor Relations
5200 Illumina Way
San Diego, CA 92122

858.291.6421
[email protected]

Transfer Agent

Computershare Trust Company, N.A.
Courier Delivery:
P.O. Box 43006
Providence RI 02940-3006
Overnight Delivery:
150 Royall St. STE 101
Canton, MA 02021

877.373.6374
www.computershare.com

Tools & Links

Email Alerts
Latest Presentation
SEC Filings
CSR Report

Innovative technologies

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

For Research Use Only. Not for use in diagnostic procedures (except as specifically noted).

All trademarks are the property of Illumina, Inc. or their respective owners.
For specific trademark information, see www.illumina.com/company/legal.html.